United Therapeutics Corporation — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; unaudited. Comparisons are with Q1 2023 unless otherwise noted. The company is a biotechnology business focused on therapies for chronic and life-threatening conditions and technologies to expand the availability of transplantable organs.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $677.7 million | $506.9 million | +34% |
| Gross profit | $604.8 million | $454.6 million | +33% |
| Gross margin | 89.2% | 89.7% | Down 0.5 percentage points |
| Operating income | $356.3 million | $284.4 million | +25% |
| Operating margin | 52.6% | 56.1% | Down 3.5 percentage points |
| Net income | $306.6 million | $240.9 million | +27% |
| Diluted EPS | $6.17 | $4.86 | +27% |
| Operating cash flow | $376.5 million | $374.8 million | Nearly flat |
Revenue growth was led by Tyvaso: Tyvaso DPI sales rose 92% to $227.5 million; nebulized Tyvaso rose 21% to $145.0 million; combined Tyvaso sales increased 56% to $372.5 million. Orenitram rose 20% to $106.2 million and Unituxin rose 19% to $58.4 million. Remodulin increased 5% to $128.0 million, while Adcirca declined 12% to $6.4 million. Management cited Tyvaso DPI uptake, patient growth and, to a lesser extent, price increases; nebulized Tyvaso also benefited from the absence of prior-year distributor destocking.
Operating expenses increased 44% to $321.4 million. SG&A rose 65% to $144.4 million, primarily from higher legal and personnel costs and a year-over-year swing in share-based compensation. R&D increased 26% to $104.1 million, reflecting organ-manufacturing programs and TETON trials. The effective tax rate rose to 23% from 17%, mainly because of lower excess tax benefits from share-based compensation.
Cash, liquidity and debt
- Cash and cash equivalents were $1.252 billion at March 31, 2024; current and non-current marketable investments were $1.456 billion and $1.492 billion. Combined cash and investments totaled $4.200 billion, down $704.2 million from year-end 2023.
- Operating cash flow was $376.5 million. Investing activities provided $735.3 million, including $831.8 million of proceeds from sales of marketable securities. Financing activities used $1.068 billion, principally for a $1.0 billion accelerated share repurchase and $100 million of debt repayment. Cash increased $43.8 million during the quarter.
- Credit facility borrowings were $600 million, down from $700 million at year-end. The company classified $400 million as current because it intends to repay that amount within one year. The facility maturity was extended to March 2029; the company reported compliance with its covenants.
- Stockholders’ equity fell to $5.338 billion from $5.985 billion, primarily reflecting the share repurchase. The initial delivery under the repurchase was 3,275,199 shares; final settlement and final share count remained pending.
Outlook, developments and risks
- Management expects near-term revenue growth to be driven mainly by continued Tyvaso DPI and PH-ILD patient growth, Orenitram utilization, and modest price increases. No specific revenue or earnings guidance was provided.
- The company budgeted approximately $500 million in capital expenditures for 2024–2026, largely for a Tyvaso DPI manufacturing facility, and expects to fund this spending from cash on hand. Commercial-scale xenotransplantation facilities could substantially increase capital spending if pursued.
- Key development programs include Phase 3 TETON studies of nebulized Tyvaso for IPF and progressive pulmonary fibrosis, and the Phase 3 ADVANCE OUTCOMES study of ralinepag for PAH. The company plans to begin a Phase 1 miroliver ELAP study in 2024. Trial outcomes and regulatory approvals remain uncertain.
- Competition is a significant risk. Merck’s Winrevair was approved in March 2024. Liquidia’s Yutrepia could compete with Tyvaso products: a court permitted the FDA to grant final approval for Yutrepia in March, while related patent and PH-ILD indication disputes remained unresolved at filing. An appellate stay request was pending.
- Other material legal matters include the Sandoz damages trial over a remaining breach-of-contract claim; appeals and proceedings concerning the company’s 340B contract-pharmacy policy; and patient-assistance-related litigation. The company said it could not reasonably estimate potential losses in the Sandoz matter. Humana and United filed new Maryland lawsuits on April 24, 2024 after earlier federal complaints were dismissed.
- The Inflation Reduction Act’s Part D redesign supported increased utilization for some products in 2024, but future discounts and payer concessions may pressure Tyvaso DPI and Orenitram revenues. CMS deemed the company a “specified small manufacturer”; management was still evaluating the impact.
- Concentration is notable: two U.S. distributors represented 51% and 34% of total revenue, respectively. The company also cited reliance on third-party manufacturing, reimbursement and pricing pressure, patent challenges, generic competition, clinical and regulatory uncertainty, and the complexity of organ-manufacturing programs.
Important facts for investors to verify
- Whether Tyvaso DPI growth continues and whether sales trends reflect patient demand rather than distributor ordering or inventory timing.
- Final share count, price and settlement adjustments for the $1.0 billion accelerated repurchase, and the intended repayment of $400 million of current-classified debt.
- Developments in Liquidia/Yutrepia proceedings and any FDA approval or commercial launch that could affect Tyvaso sales.
- Progress, enrollment and results for the TETON and ADVANCE OUTCOMES trials, and the timing and cost of manufacturing expansion.
- Potential financial exposure from litigation, 340B policy disputes, IRA discounts and rebates, and any changes in the company’s liquidity or capital-spending plans.